

**Stable Angina Guideline  
Guideline Development Group (GDG) Meeting-6  
10 am – 16 pm Friday 26<sup>th</sup> Feb 2010  
NCGC Meeting Room, National Clinical Guidelines Centre, Royal College  
of Physicians, Regents Place, 338 Euston Rd, London NW1 4BT**

**Minutes**

***Present***

***GDG***

Professor Adam Timmis	GDG Chair	AT
Dr Robert Henderson	GDG Clinical Advisor (Cardiologist)	RH
Mr Christopher Blauth	Consultant Surgeon	CB
Dr Maurice Pye	Consultant Cardiologist	MP
Mr Aidan McDermott	Cardiovascular Clinician	AM
Dr Roger Till	Patient Member	RT
Ms Liz Clark	Patient Member	LC
Mr Sotiris Antoniou	Clinical Pharmacist	SA
Dr Charles Peebles	Consultant Cardiac Radiologist	CP
Dr Jonathan Shribman	GP (SI Cardiology)	JS
Dr Leonard Jacob	GP (SI Cardiology)	LJ

***NICE***

Mr Andrew Gyton	NICE Co-ordinator	AG
-----------------	-------------------	----

***NCGC***

Dr Norma O'Flynn	NCGC Clinical Director	NOF
Dr Sharangini Rajesh	NCGC Research Fellow	SR
Ms Elisabetta Fenu	NCGC Health Economist	EF
Dr Panos Kefalas	NCGC Project Manager	PK
Dr Maggie Westby	NCGC Clinical Effectiveness Lead	MW

***Apologies***

Ms Helen O'Leary	Clinical Nurse	HOL
Dr Kevin Fox	Consultant Cardiologist	KF
Ms Sarah Willett	NICE Commissioning Manager	SW

The Chair welcomed the GDG to the 6th Stable Angina (SA) guideline development group (GDG) meeting and briefed the group on the meetings objectives.

Declarations of interest were received from:

- (MP) who informed the GDG that he received an honorarium payment of £350 from Pfizer to speak at a meeting on Statins in February 2010
- (SA) who informed the GDG that he attended a study event (State of the Heart) which was sponsored by AstraZeneca however the event was unrelated to stable angina and any of the drugs associated with its treatment
- (RH) who informed the GDG that he received honorarium payments for participation in the following two conferences:
  - ACS Challenge (Manchester) sponsored by Pfizer and Lilly
  - PPCI Challenge (Manchester) sponsored by Lilly UK, Daichi-Sankyo UK, and Boston Scientific

All other GDG members declared that they knew of no personal specific, personal non-specific, non-personal specific or non-personal non-specific interest in the development of this guideline.

(SR) presented the draft evidence reviews on the clinical effectiveness of Pharmacological vs Revascularisation (PCI or CABG) interventions for Stable Angina. Evidence was presented separately for Multi-vessel and Single-vessel disease and for different lengths of trial duration (short, medium, long-term follow-ups). The main outcomes analysed were Death, Cardiac Death, MI/Non Fatal MI, Stroke, Non Protocol Revascularisation, Free of Angina. Outcomes were also presented separately for the following sub-groups: Older Age, 2 Vessel Disease, 3 Vessel Disease. (EF) presented health-economic evidence for Pharmacological vs Revascularisation interventions and discussed development of potential economic model for the guideline. (MW) provided background information on Individual Patient Data and commented on such evidence available comparing pharmacological vs CABG in stable angina patients. The

GDG discussed both the clinical and health-economic evidence and began to draft recommendations based on the evidence provided. Review protocols for later meeting topics were also discussed.

#### SUMMARY AND ANY OTHER BUSINESS

The GDG agreed and signed off the minutes from the meeting on the 26th of March 2010.

Next GDG Meeting 26th of March 2010.

CLOSE